Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Current Deferred Revenue for 8 consecutive years, with $194000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 84.91% to $194000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $194000.0 through Dec 2025, down 84.91% year-over-year, with the annual reading at $194000.0 for FY2025, 84.91% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $194000.0 at Rhythm Pharmaceuticals, down from $1.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $9.4 million in Q1 2022, with the low at $194000.0 in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $2.3 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue changed 0.0% in 2024, then plummeted 84.91% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $7.0 million in 2021, then plummeted by 79.51% to $1.4 million in 2022, then decreased by 10.32% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then tumbled by 84.91% to $194000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $194000.0, $1.3 million, and $1.3 million for Q4 2025, Q4 2024, and Q3 2024 respectively.